Please login to the form below
Astellas to close US urology research facility
Work at Urogenix, North Carolina site will end by the end of the year
Astellas is to close its Urogenix urology drug discovery facility in North Carolina, with the loss of 13 jobs, by the end of the year.
The Japanese pharma company acquired the facility from Dynogen Pharmaceuticals in 2006 and gave it a particular focus on researching new treatments for lower urinary tract disorder.
Astellas will transfer its urology research activities to Astellas' Tsukuba Research Center in Japan and said the decision to shut down the unit would allow it to optimise its research and development resource allocation.
Featured jobs
- Senior Brand Manager - Harlow
- Competitive
- Sales Manager - Media Publishing – Cheshire
- 25,000 to 35,000 per annum
- UK Marketing Director
- 80,000 to 100,000 per annum
- Group Account Director –Healthcare Advertising
- Neg
Subscribe to our email news alerts
- Achieving an aligned business intelligence capability - fact or fiction?
- Global biosimilars market to reach $2.45bn in 2013
- Bringing trial data out of the shadows
- Novartis gets FDA green light for new Ilaris indication
- Brazil eHealth pilot improves healthcare access for city poor
- Amgen and Novartis partner with biotech venture capital firm
- Travyn Rhall takes global CEO role at Millward Brown
- Death leads to recall of batch of Takeda's Rienso in Switzerland
- Astellas gets first OK for prostate drug Vesomni
- Edelman appoints Red Health's Paul Gittins
- Merck & Co inches closer to US green light for insomnia drug
- GSK awarded $200m by US government for antibiotic research
PMHub
Add my companynitrogen
At nitrogen being creative is part of everyone’s role, whether they’re a science writer, account handler or digital ...
Latest intelligence
- Clinical trial regulation in Mexico
- Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing...
- How can pharma deliver returns on increased digital investment?
- Independent online professional networks work best as part of a multi-channel campaign ...
- The impact of Hollande's healthcare reforms in France
- A tougher environment for pharma, with market access and regulatory challenges...
Quick links
